Much of Merck & Co.'s success in fighting lawsuits related to Vioxx has centered around the argument that the drug posed cardiovascular risks only to those who took it for 18 months or longer. Now plaintiffs' lawyers are salivating over evidence they hope could support their argument that even patients who used the painkiller for short periods were in danger. 

In coming weeks The New England Journal of Medicine is expected to publish data from a study looking at Vioxx as a potential treatment for colon cancer. The clinical trial, which was halted when Vioxx came off the market in 2004, is expected to show that some patients suffered heart attacks within a year of starting the drug. "It has become clear from a variety of studies that there is increased risk with short-term use of the drug," says Thomas R. Kline, a member of the plaintiffs' steering committee for federal Vioxx litigation.

While Merck declined to comment on the study until it is published, its outside counsel, Ted Mayer, points out that some data from it already were presented at a medical meeting and had been used as fodder in courtroom debates. With 10 of 15 liability rulings having gone in Merck's favor, the company's lawyers remain confident of their ability to argue that it properly warned patients of the risk. "Looking at the totality of the data, you don't see support for a short-term effect," says Mayer. "We hope juries will put [the new study] in context."

As the debate continues, another potential source of pain may be lying in wait. On July 3 a U.S. district court judge in Louisiana paved the way for the release of Vioxx-related e-mails and other material that Merck had tried to keep out of the hands of plaintiffs' lawyers. "We're anxious to get ahold of these documents," says Kline. Merck plans to file objections to the ruling.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Merck to pay $830 million to settle investors’ Vioxx...

Merck announced Friday it will pay $830 million to settle investor complaints accusing it of committing...

Merck to pay nearly $1 billion for illegal marketing...

American pharmaceutical company Merck, Sharp & Dohme has agreed to pay $950 million to resolve criminal...

Merck paying more than 3,100 vioxx death claims

Merck & Co. is paying claims by the families of more than 3,100 users of its Vioxx painkiller who...

Settlement limits insurers' claims in Vioxx deal

TRENTON, N.J. (AP) -- Former Vioxx users getting part of a $4.85 billion settlement ending most personal...

Persistence pays in Vioxx litigation

Plaintiffs get close to $5B, but Merck could have done a lot worse. Attorneys who spent nearly one year...

Vioxx settlement payments to begin in August

Merck & Co., manufacturer of Vioxx, announced it will make the first payment of $500 million on Aug....

Thank you for all your hard work

Thank you for all your hard work over the past years on my behalf and so many others. God bless you all.

—Ella